Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | AGER | Q15109 | 1/20 | 0.57 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9858538 | 0.85 | KDM4E (0.55) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL5252687 | 0.84 | KDM4E (0.59) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL2782918 | 0.82 | KDM4E (0.62) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL188175 | 0.82 | NAPRT (0.58) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL14515519 | 0.82 | KDM4E (0.57) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL123202 | 0.82 | KDM4E (0.57) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL242926 | 0.82 | SMN1; SMN2 (0.58) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL497429 | 0.82 | PARP1 (0.53) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL3931891 | 0.82 | NAPRT (0.58) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 | |
| SCHEMBL8534431 | 0.82 | ALDH1A1 (0.57) | KDM4ETDP1ALDH1A1L3MBTL1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493304-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2012-09-05 | — | — | EP | claimed |
| JP-6199799-A | — | — | None | — | — | JP | disclosed |
| EP-4301744-A1 | NICOTINAMIDE RIPK1 INHIBITORS | AbbVie Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20230159507-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159507-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023018643-A1 | NICOTINAMIDE RIPK1 INHIBITORS | ABBVIE INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-11548880-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4046988-A1 | 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-3880654-B1 | 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | NIKANG THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| EP-3820474-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | Nikang Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210047309-A1 | MODULATORS OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10683285-B2 | Modulators of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-2638042-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012064910-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-18 | — | — | WO | disclosed |
| EP-2111400-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | AstraZeneca AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008085117-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| JP-H06199799-A | PRODUCTION OF AZAPHTHALIDE DERIVATIVE | KYOWA HAKKO KOGYO CO LTD | 1994-07-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | ADORA2A, ADORA1, ADORA3 | KDM4E 3550/4885TDP1 2781/4885ALDH1A1 944/4885 |
| US-10683285-B2 | Modulators of hemoglobin | HBG1, HBG2, HBB | KDM4E 1774/4885TDP1 3819/4885ALDH1A1 3168/4885 |
| US-20210047309-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | KDM4E 1774/4885TDP1 3819/4885ALDH1A1 3168/4885 |
| US-20230159507-A1 | MODULATORS OF HEMOGLOBIN | HBG1, HBG2, HBB | KDM4E 1774/4885TDP1 3819/4885ALDH1A1 3168/4885 |
| US-11548880-B2 | Modulators of hemoglobin | HBG1, HBG2, HBB | KDM4E 1774/4885TDP1 3819/4885ALDH1A1 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.